Clinical trial
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic…
NCT00118196 · Medical University of South Carolina, Other · Terminated
Key facts
| NCT number | NCT00118196 |
|---|---|
| Title | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
| Official title | A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes |
| Lead sponsor | Medical University of South Carolina, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | arsenic trioxide, azacitidine |
| Enrollment | 1 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 11, 2006 |
| Completion | Aug 11, 2006 |
| First posted | Jul 11, 2005 |
| Last update posted | May 11, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: